View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Rune Majlund Dahl
  • Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK900.00) - Underlying soft GLP-1 sales

We forecast a soft Q1, with 17.3% LCY sales growth and 13.8% LCY operating profit growth due to subdued prescriptions. While we estimate Ozempic sales c0.5% below consensus, we are c1.2% above for Wegovy, as we include DKK1bn in sales related to Wegovy US inventories. We see likely relief from potential unchanged 2025 LCY guidance, supported by improved Wegovy supply and fading pressure from compounders. We reiterate our BUY and DKK900 target price.

Rune Majlund Dahl
  • Rune Majlund Dahl

Zealand Pharma (Buy, TP: DKK1000.00) - Focus on pipeline progression

We expect an uneventful Q1 report, with investor focus on top-line results from the dapiglutide phase Ib obesity trial (due in Q2), which could help provide clarity on the positioning of the molecule in obesity and inflammation. For petrelintide, we have reduced our peak sales forecast to cUSD10.0bn (cUSD10.8bn) on increased competition from GUBamy. We reiterate our BUY but have cut our target price to DKK1,000 (1,150).

Carole Braudeau
  • Carole Braudeau

Credit Morning 04/24/2025

French retail sales down 2.4% in March + Q1 update|Fnac Darty: decent Q1 sales, strong performance in Southern Europe, guidance confirmed.|Saipem: good set of Q1 2025 results|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 24/04/2025

Baisse de 2,4% des ventes retail en France au mois de mars + point sur le T1|Fnac Darty : un CA T1 correct, bonne performance en Europe du Sud, guidances confirmées|Saipem: good set of Q1 2025 results|

Andreas Riemann ... (+2)
  • Andreas Riemann
  • Wim Gille
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch